Latest Insider Transactions at Precision Biosciences Inc (DTIL)
This section provides a real-time view of insider transactions for Precision Biosciences Inc (DTIL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PRECISION BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PRECISION BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
3,012
-9.55%
|
$24,096
$8.19 P/Share
|
|
Nov 04
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
588
-6.87%
|
$4,704
$8.19 P/Share
|
|
Nov 02
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,605
+9.32%
|
-
|
|
Nov 02
2024
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,443
+23.04%
|
-
|
|
Nov 02
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
1,836
+17.67%
|
-
|
|
Jun 10
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
50
-0.07%
|
$550
$11.79 P/Share
|
|
Jun 10
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
93
-1.36%
|
$1,023
$11.79 P/Share
|
|
Jun 07
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
163
+0.24%
|
-
|
|
Jun 07
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
454
+1.42%
|
-
|
|
Jun 07
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
301
+4.23%
|
-
|
|
May 08
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
833
+11.34%
|
$9,996
$12.0 P/Share
|
|
May 08
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
833
+1.2%
|
$9,996
$12.0 P/Share
|
|
May 08
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,334
+21.18%
|
$100,008
$12.0 P/Share
|
|
May 08
2024
|
Michael Amoroso President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,334
+27.38%
|
$100,008
$12.0 P/Share
|
|
May 04
2024
|
Melinda Brown |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Stanley Frankel |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+49.7%
|
-
|
|
May 04
2024
|
Geno J Germano |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Samuel C. Wadsworth |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Kevin Buehler |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+48.89%
|
-
|
|
May 04
2024
|
Shari Lisa Pire |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 02
2024
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
1,526
-9.98%
|
$15,260
$10.32 P/Share
|
|
May 02
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
290
-6.07%
|
$2,900
$10.32 P/Share
|
|
May 02
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
154
-0.23%
|
$1,540
$10.32 P/Share
|
|
May 02
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
272
-4.57%
|
$2,720
$10.32 P/Share
|
|
May 01
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,702
+6.98%
|
-
|
|
May 01
2024
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,417
+18.26%
|
-
|
|
May 01
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
982
+17.05%
|
-
|
|
May 01
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
519
+0.76%
|
-
|
|
May 01
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
918
+13.36%
|
-
|
|
Apr 30
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
238
-5.9%
|
$2,380
$10.03 P/Share
|
|
Apr 26
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
868
+17.71%
|
-
|
|
Feb 29
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
506
+2.36%
|
$9,108
$18.5 P/Share
|
|
Feb 29
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,006
+1.47%
|
$12,072
$12.42 P/Share
|
|
Jan 23
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
28,000
-1.39%
|
$0
$0.37 P/Share
|
|
Jan 22
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
21,287
-12.35%
|
$0
$0.36 P/Share
|
|
Jan 22
2024
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
137,390
-27.82%
|
$0
$0.36 P/Share
|
|
Jan 22
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,526
-18.48%
|
$0
$0.36 P/Share
|
|
Jan 20
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
59,345
+25.62%
|
-
|
|
Jan 20
2024
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
266,720
+35.07%
|
-
|
|
Jan 20
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
116,690
+15.97%
|
-
|
|
Jan 20
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,015
+3.59%
|
-
|
|
Jan 20
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,012
+34.0%
|
-
|
|
Nov 03
2023
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
16,023
-12.42%
|
$0
$0.4 P/Share
|
|
Nov 03
2023
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
125,025
-35.51%
|
$0
$0.4 P/Share
|
|
Nov 02
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
55,077
+29.92%
|
-
|
|
Nov 02
2023
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
283,390
+44.59%
|
-
|
|
Nov 02
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,188
+17.86%
|
-
|
|
Aug 31
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,951
+1.51%
|
$0
$0.39 P/Share
|
|
Aug 31
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,175
+0.27%
|
$0
$0.39 P/Share
|
|
Aug 31
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,443
+6.86%
|
$0
$0.39 P/Share
|